Merck and researchers from the Clinical Trial Service Unit at the University of Oxford recently announced positive results for the REVEAL Study.
REVEAL, which stands for Randomized Evaluation of the Effects of Anacetrapib through Lipid modification, was an outcomes study of anacetrapib, Merck’s investigational cholesteryl ester transfer protein (CETP) inhibitor.
30,449 patients took part in the study; these patients had atherosclerotic vascular disease and were receiving LDL-C lowering treatment with atorvastatin. The study showed that anacetrapib reduced the risk of major coronary events by nine percent when compared to a placebo.
Dr. Martin Landray of the University of Oxford, the co-principal investigator of the trial, presented the results at the European Society of Cardiology Congress, and simultaneously published in the online edition of The New England Journal of Medicine.
“Despite treatment advances in recent years, patients with cardiovascular disease remain at risk for cardiovascular events. We are pleased that adding anacetrapib to statin therapy resulted in a further reduction of major coronary events in REVEAL,” said Dr. Roy Baynes, senior vice president, head of clinical development and chief medical officer, Merck Research Laboratories, in a statement. “This trial helps to advance our understanding of the effects of anacetrapib on cardiovascular risk, and we are grateful to the study leaders at Oxford, TIMI, the many investigators, and the thousands of patients who participated in this study for their efforts.”